低剂量全肺照射在中重度新型冠状病毒肺炎中有效性的Meta分析

Efficacy of low dose whole-lung irradiation for the treatment of moderate to severe COVID-19 pneumonia:Meta-analysis

目的基于现有证据系统评价低剂量全肺照射在新型冠状病毒肺炎中的疗效。方法检索Pubmed、Embase、Cochrane Library、Web of Science、Google scholar、Scoupus、中国知网、万方数据库、维普数据库中截止到2022年5月所有与低剂量全肺照射治疗新型冠状病毒肺炎有关的文献。由两名研究者独立进行文献的筛选,对于符合纳入标准的文献,采用盲法进行资料提取和文献质量评价。应用Revman 5.3软件进行统计分析。结果在5篇符合研究标准的临床对照研究中,共包含194例患者。与最佳支持治疗相比,接受低剂量全肺照射患者在临床康复率、经口气管插管率、影像学改善率和28 d总生存期方面差异均无统计学意义(P>0.05)。结论低剂量全肺照射在新型冠状病毒肺炎患者中无显著的疗效。不推荐常规使用低剂量全肺照射治疗中度至重度新型冠状病毒肺炎患者。

Objective To systematically evaluate the efficacy of low dose whole-lung irradiation in COVID-19 pneumonia based on the present evidence.Methods All literature related to the application of low dose whole-lung irradiation in COVID-19 pneumonia were retrieved from Pubmed,Embase,the Cochrane Library,Web of Science,Google scholar,Scoupus,CNKI,Wanfang database,VIP database until May 2022.Two researchers independently screened the literature.For the literature that met the inclusion criteria,both data extraction and literature quality evaluation were blinded.Revman 5.3 software was used for statistical analysis.Results A total of 5 controlled clinical trials involving 194 patients met the inclusion criteria.No statistically significant differences were detected in the low dose whole-lung irradiation group compared with the best supportive care group for clinical recovery rates,intubation rates,radiographic improvement rates and 28 d-overall survival.Conclusions In patients of COVID-19 pneumonia,low dose whole-lung irradiation conferred no significant benefit to clinical outcomes.Currently,the routine use of low dose whole-lung irradiation for the treatment of moderate to severe COVID-19 pneumonia is not recommended.